Transaction Includes New Investors Salus Partners and Quest for Growth
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, announced today that it has raised CHF 9 million ($9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest AG, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners participated for a total of CHF 5.3M, with a further CHF 3.7M raised from new investors including Salus Partners SA and Quest for Growth NV. Sequana Medical will use these funds to expand current business for its proven fluid management systems through new indications in heart disease and to pursue U.S. marketing approvals.
Sequana Medical presented the alfapump® system at this year’s Viszeralmedizin Congress in Leipzig, Germany
Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre.
Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump® system.
Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system.
Sequana Medical presents exciting clinical updates on the alfapump® System at this year’s International Liver Congress in Vienna.
Sequana Medical is delighted to be attending this year’s International Liver Congress in Vienna to present alfapump with DirectLink Technology.
Sequana Medical is pleased to announce the appointment of Medinistros SAS as exclusive distributor for the alfapump system in Colombia.
Sequana Medical supports Bristol hepatologist Dr Anne McCune’s Sahara Challenge in aid of the British Liver Trust
Sequana Medical is proud to support Dr Anne McCune in her brave trek across the Sahara in aid of the British Liver Trust.
Sequana Medical’s new alfapump® with DirectLink Technology improves the care of patients with challenging refractory ascites
Technological advances in Sequana Medical’s alfapump system will allow patients and their doctors to better manage the distressing symptoms of refractory ascites. With enhanced communications enabled by the new DirectLink Technology, clinicians will now be able to monitor the alfapump remotely.
Sequana Medical is delighted to be attending this year’s International Liver Congress in London.
Sequana Medical is delighted to report that HUG, the university hospital of Geneva, is now offering the alfapump system as a treatment option for patients suffering from refractory ascites.
The alfapump system featured once again in the British press, this time in the ‘Sun’ newspaper.